awd-12-281 and Psoriasis

awd-12-281 has been researched along with Psoriasis* in 1 studies

Reviews

1 review(s) available for awd-12-281 and Psoriasis

ArticleYear
AWD-12-281 (inhaled) (elbion/GlaxoSmithKline).
    Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:11

    elbion (formerly ASTA Medica) and GlaxoSmithKline are developing an inhaled formulation of AWD-12-281 for the potential treatment of chronic obstructive pulmonary disease (COPD). By May 2005, phase II trials of this 5-hydroxyindole PDE4 inhibitor for COPD were ongoing.

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Administration, Topical; Amides; Aminopyridines; Animals; Benzamides; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dermatitis, Atopic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Indoles; Inflammation; Lipopolysaccharides; Ovalbumin; Phosphodiesterase Inhibitors; Psoriasis; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Structure-Activity Relationship

2005